Mereo BioPharma Group plc (MREO)

$1

+0.01 (+1.01%)
Rating:
Recommendation:
-
Symbol MREO
Price $1
Beta 0.758
Volume Avg. 0.70M
Market Cap 124.986M
Shares () -
52 Week Range 0.301-1.85
1y Target Est -
DCF Unlevered MREO DCF ->
DCF Levered MREO LDCF ->
ROE -111.62% Strong Sell
ROA -57.67% Strong Sell
Operating Margin -
Debt / Equity 55.26% Buy
P/E 9.09 Strong Buy
P/B 1.23 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest MREO news


Dr. Denise Scots-Knight
Healthcare
Biotechnology
NASDAQ Global Market

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.